Abstract
The arrival of tyrosine kinase inhibitors (TKI) in first line of treatment for advanced non-small cell lung cancer with EGFR mutations has changed the strategy of treatment of theses patients. Indeed, response rates in these cases reach around 60 to 70%, with a progression-free survival greatly prolonged, up to 10 months. It seems that these patients with mutated tumor benefit from TKI whatever the treatment line, with the same efficacy. So, the best sequence of treatment (TKI in first line then chemotherapy in second line, or the opposite) needs still to be defined in this sub-group of NSCLC. The choice has to take in account the data of efficacy of TKIs and chemotherapy in the EGFR mutated tumors, with an anticipation of subsequent lines from the first line. Besides, data of toxicity and quality of life have also to be considered.
| Translated title of the contribution | What is the best sequence of treatment for patients with EGFR mutations? |
|---|---|
| Original language | French |
| Pages (from-to) | S24-S29 |
| Journal | Revue de Pneumologie Clinique |
| Volume | 67 |
| Issue number | SUPPL. 1 |
| DOIs | |
| Publication status | Published - 1 Jun 2011 |